The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...

NVO has been struggling on the charts since its late-April bottom at $57, with recent pressure at the $70 region. So far in ...

Novo Nordisk's new CEO, Maziar Mike Doustdar, is tasked with revitalizing the company's flagging sales and addressing ...

Hit by rising medical care costs and squeezed by government changes, the health care conglomerate acknowledges “pricing and operational mistakes” affected its bottom line and has outlined steps to ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Novo Nordisk fell by 21.83 percent on Tuesday to end at $53.94 apiece as investors unloaded positions following the company’s ...

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk ( NVO) continued its downward spiral and fell 3.8% in premarket trade, a day after the Danish drugmaker slashed ...

Novo Nordisk on Tuesday slashed its outlook for 2025 sales growth and said it had appointed veteran insider Maziar Mike ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk's new CEO, Maziar Mike Doustdar, faces challenges in reviving waning sales and shares in the weight-loss drug ...